Earnings / Biotechnology
EyePoint cuts 53% of its workforce and ends wet AMD trials early
The company estimated $118 million of cash at September 30 and about $30 million in annualized savings, with pivotal Phase 3 DME topline data still guided for the fourth quarter of 2027 after LUCIA missed its primary endpoint.